- call +1-201-465-4211
- email sales@mrinsights.biz
Meningococcal disease is a severe infection of meninges, the thin layers of tissue covering brain and spinal cord, caused by the bacteria Neisseria meningitidis. This bacteria can also cause bloodstream infections (septicemia). Bacterial meningitis is severe because of rapid onset and a significant risk of death associated with infection. Infection of Neisseria meningitidis may also result in mental retardation, deafness and epilepsy. 12 strains of N. meningitidis have been identified, 6 of which (A, B, C, W, X and Y) are capable enough to cause epidemics. Meningococcal septicaemia is a rare but fatal form of meningococcal disease characterized by a haemorrhagic rash and rapid circulatory collapse.
Scope of the Report:
This report focuses on the Meningococcal Disease Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Meningococcal Disease Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Pfizer
GlaxoSmithKline
Sanofi Pasteur
Novartis
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Injectable
Oral
Market Segment by Applications, can be divided into
Hospitals
Drugstores
Others
There are 15 Chapters to deeply display the global Meningococcal Disease Drugs market.
Chapter 1, to describe Meningococcal Disease Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Meningococcal Disease Drugs, with sales, revenue, and price of Meningococcal Disease Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Meningococcal Disease Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Meningococcal Disease Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Meningococcal Disease Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Meningococcal Disease Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Injectable
1.2.2 Oral
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Drugstores
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 Meningococcal Disease Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pfizer Meningococcal Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 GlaxoSmithKline
2.2.1 Business Overview
2.2.2 Meningococcal Disease Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 GlaxoSmithKline Meningococcal Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Sanofi Pasteur
2.3.1 Business Overview
2.3.2 Meningococcal Disease Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Sanofi Pasteur Meningococcal Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Novartis
2.4.1 Business Overview
2.4.2 Meningococcal Disease Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Novartis Meningococcal Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Meningococcal Disease Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Meningococcal Disease Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Meningococcal Disease Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Meningococcal Disease Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Meningococcal Disease Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Meningococcal Disease Drugs Market Analysis by Regions
4.1 Global Meningococcal Disease Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Meningococcal Disease Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Meningococcal Disease Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
4.5 South America Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
5 North America Meningococcal Disease Drugs by Countries
5.1 North America Meningococcal Disease Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Meningococcal Disease Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Meningococcal Disease Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
6 Europe Meningococcal Disease Drugs by Countries
6.1 Europe Meningococcal Disease Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Meningococcal Disease Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Meningococcal Disease Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
6.3 UK Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
6.4 France Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Meningococcal Disease Drugs by Countries
7.1 Asia-Pacific Meningococcal Disease Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Meningococcal Disease Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Meningococcal Disease Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
7.5 India Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
8 South America Meningococcal Disease Drugs by Countries
8.1 South America Meningococcal Disease Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Meningococcal Disease Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Meningococcal Disease Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Meningococcal Disease Drugs by Countries
9.1 Middle East and Africa Meningococcal Disease Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Meningococcal Disease Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Meningococcal Disease Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Meningococcal Disease Drugs Sales and Growth Rate (2013-2018)
10 Global Meningococcal Disease Drugs Market Segment by Type
10.1 Global Meningococcal Disease Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Meningococcal Disease Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Meningococcal Disease Drugs Revenue and Market Share by Type (2013-2018)
10.2 Injectable Sales Growth and Price
10.2.1 Global Injectable Sales Growth (2013-2018)
10.2.2 Global Injectable Price (2013-2018)
10.3 Oral Sales Growth and Price
10.3.1 Global Oral Sales Growth (2013-2018)
10.3.2 Global Oral Price (2013-2018)
11 Global Meningococcal Disease Drugs Market Segment by Application
11.1 Global Meningococcal Disease Drugs Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Drugstores Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Meningococcal Disease Drugs Market Forecast (2018-2023)
12.1 Global Meningococcal Disease Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Meningococcal Disease Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Meningococcal Disease Drugs Market Forecast (2018-2023)
12.2.2 Europe Meningococcal Disease Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Meningococcal Disease Drugs Market Forecast (2018-2023)
12.2.4 South America Meningococcal Disease Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Meningococcal Disease Drugs Market Forecast (2018-2023)
12.3 Meningococcal Disease Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Meningococcal Disease Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Meningococcal Disease Drugs Market Share Forecast by Type (2018-2023)
12.4 Meningococcal Disease Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Meningococcal Disease Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Meningococcal Disease Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Meningococcal Disease Drugs Picture
Table Product Specifications of Meningococcal Disease Drugs
Figure Global Sales Market Share of Meningococcal Disease Drugs by Ty
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
